The clinical management of EGFR-mutant NSCLC faces significant challenges, including the limited efficacy of osimertinib monotherapy in controlling brain metastases and the inevitable development of acquired resistance [61, 62]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.